TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 17 years of age~* Are scheduled for uncomplicated unilateral cataract surgery~* Signature of the subject or parent(s) or legally authorized representative on the Informed Consent Form, and when appropriate the minor's assent in accordance with local regulations~* Are willing and able to follow all instructions and attend all study visits~* Are willing to avoid disallowed medication for the duration of the study~* If female is of childbearing potential, agree to and submit a urine sample for pregnancy testing (prior to enrollment and at the end of the study) and use effective contraception for the duration of the study~* Male subjects whose female partners are not post-menopausal must agree to one of the following: 1) completely abstain from sexual intercourse, 2) use a barrier method (condoms) with spermicide during sexual intercourse for the duration of the study, 3) provide documentation for having had a vasectomy (with documented infertility)~* Additional inclusion criteria also apply~Exclusion Criteria:~* Have known sensitivity or poor tolerance to any component of the study drugs~* Have any sign of iritis or scleritis in the study eye~* Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye~* Have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to affect wound healing (e.g., diabetes mellitus, systemic connective tissue disease, severe atopic disease)~* Have known blood dyscrasia or bone marrow suppression~* Have any active corneal pathology in the study eye~* Have had radial keratotomy, corneal transplant, or LASIK in the study eye within the last 2 years~* Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine pregnancy test~* Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device~* Have a condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation~* Use of any medication the investigator feels may interfere with the study parameters~* Additional exclusion criteria also apply

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-305 (Type: EXPERIMENTAL): 0.1% dexamethasone in DuraSite® 2
- Vehicle (Type: PLACEBO_COMPARATOR): DuraSite® 2 vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Informed consent obtained prior to any study-mandated procedure,~* Males aged from 18 to 85 and postmenopausal females aged up to 85 years,~* Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,~* Subjects presenting a type I AMI including STEMI or NSTEMI.~Main Exclusion Criteria:~* Cardiogenic shock or severe hemodynamic instability,~* Cardiopulmonary resuscitation,~* Loading dose of any oral P2Y12 receptor antagonist prior to randomization,~* Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,~* Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).~* Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.~* Known clinically important anemia.~* Oral anticoagulation therapy within 7 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Selatogrel 8 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Selatogrel 16 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Disturbed Sleep Model Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight =50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive~* Healthy as judged by responsible physician.~* No clinically significant abnormality identified on the medical or laboratory evaluation and 12-lead ECG;~* The subject shows a normal sleep pattern on the basis of the evaluation of both PSG screening nights. Normal sleep will be defined as follows: LPS (Latency to persistence Sleep) \<30min., SE (Sleep Efficiency) \>85%, apnea/ hypopnea index \< 10, periodic leg movements (PLM) with arousal index \< 10. The apnea/hypopnea index is defined as the number of apneas and hyponeas divided by the total sleep time (TST) expressed in hours. PLMI is defined as the number of periodic leg movements associated with arousals or awakening divided by the total sleep time (TST) expressed in hour.~Exclusion Criteria:~* A positive result for the pre-study urine drug/ alcohol breath screen.~* Abuse of alcohol.~* Subject complains of sleep disturbances and /or is receiving treatment for sleep disorders.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ADBC sequence (Type: EXPERIMENTAL): In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
- BACD sequence (Type: EXPERIMENTAL): In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
- CBDA sequence (Type: EXPERIMENTAL): In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
- DCAB sequence (Type: EXPERIMENTAL): In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Clinical Diagnosis of recurrent Major Depressive Episode (MDE) according the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria with:~* Reported duration of the current episode of at least 4 weeks~* MADRS total score \>=26~* At least one previous MDE before the age of 60 years~Exclusion Criteria:~* Mini Mental State Exam (MMSE) \<24~* Any current anxiety disorder as defined in the DSM-IV-TR~* Current or past history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR~* Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR~* Presence or history of a clinically significant neurological disorder (including epilepsy)~* Neurodegenerative disorder (Alzheimer's disease, Parkinson disease, multiple sclerosis, Huntington disease, etc)~* Any Axis II disorder that might compromise the study~* Significant risk of suicide according to the investigator's opinion, or has a score \>=5 on item 10 of the MADRS or has made a suicide attempt in the previous 6 months~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vortioxetine 5 mg (Type: EXPERIMENTAL): None
- Duloxetine 60 mg (Type: OTHER): Active reference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung.~* Positive for translocation or inversion events involving the ALK gene locus.~* No prior systemic treatment for locally advanced or metastatic disease. Patients with brain metastases only if treated and neurologically stable for at least 2 weeks and are not taking any medications contraindicated in Exclusion Criteria~* Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome \[PRO\] measures.~Exclusion Criteria:~* Current treatment on another therapeutic clinical trial.~* Prior therapy directly targeting ALK.~* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. Appropriate treatment with anticoagulants is permitted.~* Ongoing cardiac dysrhythmias of NCI CTCAE Grade \>=2, uncontrolled atrial fibrillation of any grade, or QTc interval \>470 msec.~* Pregnancy or breastfeeding.~* Use of drugs or foods that are known potent CYP3A inducers/inhibitors Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices.~* Known HIV infection~* History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.~* Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or end-stage renal disease on hemodialysis, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Crizotinib (Type: EXPERIMENTAL): Crizotinib
- Chemotherapy (Type: ACTIVE_COMPARATOR): Chemotherapy \[Option at Investigator's Choice\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trazodone for Sleep Disorders in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fifty-five years of age or older;~* Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria;~* Hachinski Ischemia Scale score less than 5~* Mini-Mental State Examination score of O to 26~* Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week;~* For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale;~* Sleep disturbance observed was not present before the diagnosis of AD;~* Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms;~* Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal;~* Stable medications for 4 weeks prior to the screening visit;~* Having a mobile upper extremity to which to attach an actigraph;~* Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol;~* Ability to ingest oral medication and participate in all scheduled evaluations~Exclusion Criteria:~* Sleep disturbance associated with an acute illness, delirium or psychiatric disease;~* Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness~* Severe agitation;~* Unstable medical condition;~* Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit;~* Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol;~* Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol;~* Prior use of trazodone for the treatment of sleep disturbances;~* Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trazodone (Type: EXPERIMENTAL): Study group will receive trazodone 50mg
- Placebo (Type: PLACEBO_COMPARATOR): Inert pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects ≥ 42 days to ≤ 64 days of age.~2. Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements~Exclusion Criteria:~1. Subjects whose parents or legal guardians are unwilling or unable to give written informed consent to participate in the study.~2. History of previous immunization with a vaccine containing any of the 5 antigen components of investigational vaccine.~3. History of anaphylactic shock(immediate hypersensitivity reactions), urticaria or other allergic reactions after previous vaccination or known hypersensitivity to any vaccine component.~4. Administration of parenteral immunoglobulin preparation and/or blood products since birth.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 64 Days
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Mix25 Versus Mix50

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) for at least 6 months~* Have been taking sulfonylureas, biguanide, thiazolidinedione, alpha-glucosidase inhibitor, glinide, or dipeptidyl peptidase IV inhibitor, or any combination of these~* Have a qualifying hemoglobin A1c (HbA1C) value ≥7.0% and ≤11.0% at screening~* Have a body mass index (BMI) ≥18.5 and \<35.0 kilogram per square meter (kg/m²)~* Have given written informed consent to participate in the study in accordance with local regulations and the ethical review board (ERB) governing the study site~Exclusion Criteria:~* Have a diagnosis of type 1 diabetes~* Have had more than 1 episode of severe hypoglycemia within the 6 months before screening~* Have any of the following cardiovascular conditions within 3 months prior to screening: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke)~* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase levels ≥3.0 times the upper limit of the reference range at screening, as determined by the central laboratory~* Have an estimated creatinine clearance (CrCl), Cockcroft-Gault formula \<30 milliliter per minute (mL/min), as determined by the central laboratory at screening~* Have evidence of a significant, active, uncontrolled endocrine or autoimmune abnormality, as judged by the investigator~* Have an active or untreated malignancy or have been in remission from a clinically significant malignancy for \<5 years~* Have any other condition (such as, known drug or alcohol abuse or a psychiatric disorder) that may prevent the participants from following and completing the protocol~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Lispro Mix25 (Type: EXPERIMENTAL): Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
- Insulin Lispro Mix50 (Type: EXPERIMENTAL): Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 6 months~* Insulin naive. Short term insulin treatment (7 days or less within the last 6 months) is allowed~* Previous treatment with oral antidiabetic drugs for at least 4 months~* Judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen~* BMI below 40 kg/m2~* HbA1c between 7-12%~* Able and willing to perform self-plasma glucose monitoring~Exclusion Criteria:~* The receipt of any other investigational drug within 4 weeks before screening~* A history of drug or alcohol abuse within the last 12 months~* Severe, uncontrolled hypertension~* Known or suspected allergy to trial products or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zinc Supplementation in Cholera Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 3-14 years hospitalized at ICDDR, B presenting with cholera within 24 hours of onset.~* Stool output more than 4ml/kg/hour within the first 6 hours of observation period.~* Positive dark field examination~Exclusion Criteria:~* Unable to rehydrate within 6 hours~* Negative dark field examination~* Systemic illness requiring immediate administration of antibiotics.~* Received antibiotics in the 24 hours prior to hospitalization~* Patients presenting with bloody mucoid diarrhea~* Unconscious or medical emergencies

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete